Skip to main content

Insulin

No sources yet

An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.

Source summary generated November 6, 2026; this date does not indicate completed review.

Hormones
Track your own protocol free →

Quotes from three independent practitioners, with their sources. Research context only.

What it is and how it works

From the published literature on Insulin; the papers are listed at the end. Research summary, not a recommendation.

What it is

Insulin is the hormone made by the beta cells of the pancreas that controls how the body stores and uses glucose. Human insulin is a small protein of 51 amino acids in two chains (A and B) held together by disulfide bonds. It was first extracted and used to treat diabetes in Toronto in 1921-1922, and in 1982 recombinant human insulin became the first medicine made by genetically engineered bacteria; modified versions (analogues such as lispro, aspart, glargine and degludec) were later designed to act faster or last longer. The supplier lists do not state which insulin type is sold.

How it works

Insulin binds the insulin receptor, a protein on the surface of liver, muscle and fat cells that switches on a signalling chain (the PI3K-Akt pathway) inside the cell. In muscle and fat this moves glucose transporters (GLUT4) to the cell surface so glucose leaves the blood; in the liver it shuts down glucose production and promotes storage as glycogen. It also blocks the breakdown of stored fat, promotes protein building and drives potassium into cells. In type 1 diabetes the body makes almost no insulin, so injected insulin is essential for survival; in type 2 diabetes it is added when other drugs no longer control blood glucose.

What it has been studied for

  • Type 1 diabetes (DCCT trial of intensive versus conventional insulin therapy)
  • Type 2 diabetes (UKPDS trial of intensive glucose control)
  • Rapid-acting and long-acting insulin analogues
  • Hypoglycaemia as the main limit of insulin therapy
  • Non-medical misuse by bodybuilders and athletes for muscle gain

Strength of the evidence

Approved drugHuman insulin and its analogues are FDA- and EMA-approved for diabetes, with a century of clinical use and large randomized trials.

What the literature reports on safety

The main risk is hypoglycaemia (low blood sugar), which can cause confusion, seizures, coma and death; other reported effects include weight gain, low potassium and fat changes at injection sites. Non-medical use by bodybuilders to gain muscle has been documented, with hypoglycaemia reported by most users in one survey; outside diabetes care insulin is prohibited at all times by the World Anti-Doping Agency (section S4, hormone and metabolic modulators). Insulin is a prescription medicine; an unlabelled product of unstated type and strength makes the strength and onset of action unknowable, which raises the hypoglycaemia risk.

Key papers

  1. Insulin's centenary: the birth of an idea. (opens in a new tab)

    Review · Hegele RA, Maltman GM · Lancet Diabetes and Endocrinology (2020) · PMID 33129375

    Recounted the 1920 to 1922 work in Toronto that produced an effective pancreatic extract and then insulin pure enough for human use, recognized by the 1923 Nobel Prize.

  2. Insulin: The master regulator of glucose metabolism. (opens in a new tab)

    Review · Norton L, Shannon C, et al. · Metabolism (2022) · PMID 35066003

    Reviewed how insulin lowers glucose output from the liver, raises glucose uptake into muscle, liver and fat, restrains fat breakdown and widens blood vessels in muscle, and the molecular basis of these actions.

  3. Insulin analogues. (opens in a new tab)

    Review · Hirsch IB · New England Journal of Medicine (2005) · PMID 15647580

    Reviewed the rapid-acting and long-acting insulin analogues produced by small changes to the insulin molecule.

  4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. (opens in a new tab)

    Randomized trial · Diabetes Control and Complications Trial Research Group, Nathan DM, et al. · New England Journal of Medicine (1993) · PMID 8366922

    In type 1 diabetes (DCCT), intensive insulin therapy reduced the development of retinopathy by 76% and slowed eye, kidney and nerve damage compared with conventional therapy, at the cost of a two- to threefold increase in severe hypoglycaemia.

  5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). (opens in a new tab)

    Randomized trial · UK Prospective Diabetes Study (UKPDS) Group · Lancet (1998) · PMID 9742976

    In newly diagnosed type 2 diabetes, intensive control with sulphonylureas or insulin reduced small-vessel complications compared with conventional treatment, with more hypoglycaemia and weight gain.

  6. Hypoglycemia in diabetes. (opens in a new tab)

    Review · Cryer PE, Davis SN, et al. · Diabetes Care (2003) · PMID 12766131

    Described hypoglycaemia as the limiting factor in insulin treatment and explained how repeated episodes blunt the body's warning symptoms and defences.

  7. Weightlifting's risky new trend: a case series of 41 insulin users. (opens in a new tab)

    Case series · Ip EJ, Barnett MJ, et al. · Current Sports Medicine Reports (2012) · PMID 22777326

    Surveyed 41 non-diabetic insulin users recruited from fitness, bodybuilding and weightlifting websites, 95% of whom also used anabolic steroids; more than half reported hypoglycaemia, one reported losing consciousness, and most said insulin was easy to obtain.

  8. Insulin. (opens in a new tab)

    Review · Thevis M, Thomas A, et al. · Handbook of Experimental Pharmacology (2010) · PMID 20020367

    Reviewed insulin as a doping agent, why athletes misuse it, and the mass-spectrometry methods used to detect synthetic insulins in sport.

Sources checked: PubMed/PMC (E-utilities esummary on every PMID; abstract read for the weightlifter case series), written 2026-11-06.

No sources yet

None of the three teachers' sources we have indexed discuss Insulin yet. This page will fill in as sources are added.

Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.

Disclaimer: for research purposes only

All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.

Insulin — Hunter, Taylor, Bachmeyer | Reset Biology